Status:

UNKNOWN

Efficacy and Safety Study of the Combined Modality Therapy in Adenocarcinoma of the Esophago-gastric Junction

Lead Sponsor:

Medical University of Lublin

Conditions:

Adenocarcinoma of the Gastroesophageal Junction

Eligibility:

All Genders

18+ years

Phase:

PHASE2

PHASE3

Brief Summary

The high cancer related mortality has remained a significant issue of health care in Poland, Europe and worldwide. The decreasing incidence rate for carcinoma of the distal stomach and a marked trend ...

Detailed Description

Adenocarcinoma of the esophago-gastric junction (AEG) represents an aggressive disease with poor prognosis. Surgery is the traditional mainstay of treatment for patients presenting with locally advanc...

Eligibility Criteria

Inclusion

  • patients of both gender, aged more than 18, with histopathologically confirmed adenocarcinoma of the esophagogastric junction
  • medically fit to undergo a major surgery with planned thoracotomy and in general condition allowing to tolerate chemo- or chemoradiotherapy (Karnofsky Performance Status ≥70, ECOG 0-1).
  • Carcinoma of the esophagogastric junction defined as adenocarcinoma involving esophagogastric junction when its epicenter is localized within 5cm proximally or 5cm distally to the anatomical esophagogastric junction with subclassification to 3 topographic types (type I between 5cm and 1cm above; type II between 1cm above and 2cm below; type III between 2cm and 5cm below anatomic junction of the esophagus and the stomach).
  • Potentially resectable, local or locoregional cancer with clinical staging cT2-4aN0-3M0.
  • The intended number of randomized patients has been set as 100: 50 patients randomized to each therapeutic arm with assumption, that 80% of randomized patients will complete the treatment protocol.

Exclusion

  • disseminated cancer
  • poor general condition (KI \<70)
  • adenocarcinoma of the stomach
  • adenocarcinoma of the esophagus

Key Trial Info

Start Date :

January 1 2012

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2020

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT01523015

Start Date

January 1 2012

End Date

December 1 2020

Last Update

February 5 2013

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Second Department of General & Gastrointestinal Surgery & Oncological Surgery of the Alimantary Tract, Medical University of Lublin

Lublin, Lublin Voivodeship, Poland, 20-081